dabrafenib and trametinib

Details

Generic Name:

Project Status:

Not filed

Therapeutic Area:

Pediatric glioma with a BRAF V600E

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Brand Name:

Tafinlar and Mekinist

Project Line:

Reimbursement Review

Project Number:

N/A

Manufacturer Requested Reimbursement Criteria¹:

CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer

Submission Type:

Non Submission

Indications:

For the treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy. For the treatment of pediatric patients 1 year of age and older with high-grade glioma with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.

Recommendation Type:

CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Last Updated : October 16, 2023